Weekly Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings as of Jun 27, 2018

June 27, 2018 - By Margaret Staats

Seattle Genetics, Inc. (NASDAQ:SGEN) Corporate Logo
Big Money Sentiment increased to 1.61 in 2018 Q1. It has change of 0.38, from 2017Q4’s 1.23. The ratio increased due to Seattle Genetics, Inc. positioning: 24 sold and 53 reduced. 31 funds bought holdings and 93 increased holdings. Investors holded 141.83 million in 2017Q4 but now own 159.52 million shares or 12.47% more.
British Columbia Inv Management, a British Columbia – Canada-based fund reported 47,410 shs. Keybank National Association Oh reported 0% of its capital in Seattle Genetics, Inc. (NASDAQ:SGEN). Capital Fund Management Sa invested in 14,321 shs. Tower Research Capital Ltd Liability Corporation (Trc) holds 7,006 shs or 0.03% of its capital. Millennium Management Llc, a New York-based fund reported 420,209 shs. Gateway Invest Advisers Ltd Company invested 0.03% in Seattle Genetics, Inc. (NASDAQ:SGEN). Northern Trust has 0.01% invested in Seattle Genetics, Inc. (NASDAQ:SGEN). Fjarde Ap invested in 0.03% or 34,540 shs. Teacher Retirement System Of Texas has 0.01% invested in Seattle Genetics, Inc. (NASDAQ:SGEN). Rmb Cap Ltd Limited Liability Company reported 44,284 shs. Berson And Corrado Invest Advsrs Lc accumulated 20,543 shs or 0.64% of the stock. Perkins Coie Trust reported 0% stake. Fifth Third Bankshares, Ohio-based fund reported 134 shs. California Pub Employees Retirement has 0.02% invested in Seattle Genetics, Inc. (NASDAQ:SGEN). 40,500 are held by Platinum Investment Management Ltd.

Seattle Genetics, Inc. had 12 insider sales and 3 insider purchases since January 11, 2018. This’s net activity of $266.95 million. SIEGALL CLAY B sold $951,393 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) or 18,832 shs on Monday, April 9. Cline Darren S also sold $831,688 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) on Tuesday, June 12. $552,452 worth of Seattle Genetics, Inc. (NASDAQ:SGEN) shs were sold by DRACHMAN JONATHAN G. HIMES VAUGHN B sold 5,000 shs worth $292,365.

Seattle Genetics, Inc. (NASDAQ:SGEN) Ratings Coverage

In total 8 analysts cover Seattle Genetics (NASDAQ:SGEN). “Buy” rating has 7, “Sell” are 0, while 1 are “Hold”. 88% are bullish. 12 are the (NASDAQ:SGEN)’s analyst reports since January 31, 2018 according to StockzIntelligence Inc. The stock rating was maintained by SunTrust with “Hold” on Wednesday, February 7. On Wednesday, January 31 the stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Buy” rating given by RBC Capital Markets. On Friday, April 27 the stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Buy” rating given by H.C. Wainwright. On Wednesday, February 7 the firm has “Buy” rating by Needham given. The stock rating was maintained by H.C. Wainwright with “Buy” on Thursday, February 1. In Wednesday, March 21 report Morgan Stanley maintained the stock with “Overweight” rating. On Wednesday, February 14 the stock of Seattle Genetics, Inc. (NASDAQ:SGEN) has “Overweight” rating given by JP Morgan. On Wednesday, February 7 the firm has “Buy” rating given by H.C. Wainwright. On Wednesday, February 7 the stock has “Neutral” rating by Bank of America. On Wednesday, February 14 the rating was upgraded by J.P. Morgan to “Buy”. Listed here are Seattle Genetics, Inc. (NASDAQ:SGEN) PTs and latest ratings.

11/06/2018 Broker: SunTrust Rating: Buy Upgrade
27/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0000 Maintain
21/03/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $69 New Target: $67 Maintain
20/03/2018 Broker: RBC Capital Markets Rating: Buy New Target: $73.0 Maintain
14/02/2018 Broker: J.P. Morgan Rating: Buy New Target: $66.0 Upgrade
14/02/2018 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Old Target: $60 Upgrade
07/02/2018 Broker: Needham Rating: Buy New Target: $74.0 Maintain
07/02/2018 Broker: Bank of America Old Rating: Neutral New Rating: Neutral Old Target: $70 New Target: $68 Maintain
07/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $77.0 Maintain
07/02/2018 Broker: SunTrust Rating: Hold New Target: $60.0 Maintain

Ticker’s shares touched $65.39 during the last trading session after 0.43% change.Currently Seattle Genetics, Inc. is downtrending after 15.50% change in last June 27, 2017. SGEN has also 296,186 shares volume. SGEN underperformed the S&P 500 by 28.07%.

Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies to treat cancer worldwide.The firm is worth $10.35 billion. It markets ADCETRIS, an antibody-drug conjugate for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.Last it reported negative earnings. The firm also develops SGN-CD33A that is in Phase III clinical trial to evaluate SGN-CD33A in combination with hypomethylating agents in previously untreated older patients, as well as in Phase 1/2 clinical trial for patients with relapsed or refractory acute myeloid leukemia ; ASG-22ME, which is in Phase I clinical trial for Nectin-4-positive solid tumors, including bladder cancer; SGN-LIV1A that is in Phase 1 clinical trial for patients with LIV-1-positive metastatic breast cancer; and SGN-CD19A, which is in Phase II clinical trial for patients with relapsed DLBCL, as well as in Phase II trial for patients with newly diagnosed DLBCL.

A couple more Seattle Genetics, Inc. (NASDAQ:SGEN) news were announced by: Seekingalpha.com which released on June 13, 2018 “Immunomedics: Short-Term Risk, Long-Term Opportunity”, also Nasdaq.com on June 26, 2018 announced “Analysis: Positioning to Benefit within The Manitowoc, Omeros, Catabasis Pharmaceuticals, Zayo Group, Covanta …”, the next Seekingalpha.com is “Premarket analyst action – healthcare” on June 11, 2018. Streetinsider.com has article titled “SunTrust Robinson Humphrey Upgrades Seattle Genetics (SGEN) to Buy; Improving Prospects For Adcetris In 1L HL”.

Seattle Genetics, Inc. (NASDAQ:SGEN) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.